

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number  
**WO 02/42315 A2**

(51) International Patent Classification<sup>7</sup>: **C07H 17/08**,  
A61K 31/7048, A61P 31/04

Sant Celoni (ES). **LUDESCHER, Johannes** [AT/AT];  
Kleinsöll 101, A-6252 Breitenbach (AT).

(21) International Application Number: PCT/EP01/13760

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate  
Intellectual Property, Patent & Trademark Department,  
CH-4002 Basel (CH).

(22) International Filing Date:

26 November 2001 (26.11.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/253,119 27 November 2000 (27.11.2000) US  
0031355.1 21 December 2000 (21.12.2000) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,  
PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US,  
UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(71) Applicant (*for all designated States except US*): **BIO-  
CHEMIE S.A.** [ES/ES]; Ap. de Correos, 97, E-08400  
Granollers (ES).

Published:

— *without international search report and to be republished  
upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CENTELLAS**,  
Victor [ES/ES]; Plaza Joan Alsina, 8,4-2-a, E-08440  
Cardedeu (ES). **DIAGO, José** [ES/ES]; Calle Josep  
Carner, 43,5-a, E-08400 Granollers (ES). **GARCIA**,  
Rafael [ES/ES]; Pza. Mercè Rodoreda, 3, 3o, 2a, E-08470

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: MACROLIDE SOLVATES

(57) Abstract: Azithromycin in the form of a monohydrate comprising from 4.0 % to 6.5 % of water, a process for its preparation and its use in pharmaceutical compositions.



**WO 02/42315 A2**

### Macrolide solvates

The present invention relates to macrolide solvates, i.e. solvates of azithromycin and similar compounds. Azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A) is a well-known antibacterial agent, described e.g. in The Merck Index, 12<sup>th</sup> edition (1996), page 157 (item 946) and may be produced according to a known process. Azithromycin may be obtained in the form of a solvate, e.g. in the form of a hydrate, such as a monohydrate or e.g. in the form of a dihydrate. It is known that azithromycin in the form of a monohydrate may be unstable and may contain degradation products, when set out to normal air humidity conditions and azithromycin in the form of a monohydrate produced according to known methods, e.g. by precipitation with water from an ethanolic solution, may beside its instability contain a high content of residual solvents. Thus, azithromycin currently on the market is in the form of a dihydrate which is known to be stable under normal air humidity conditions.

We have now surprisingly found that azithromycin may be obtained in the form of a, e.g. crystalline, monohydrate which is stable.

In one aspect the present invention provides azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% w/w of water.

Azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% w/w of water is hereinafter designated as "azithromycin according to the present invention".

Azithromycin according to the present invention contains water from 4.0% to 6.5%. The calculated amount of water in azithromycin in the form of a composition consisting of 1 mol of azithromycin and 1 mol of water is around 2.35% w/w, but an azithromycin/water composition wherein the water content is different from 2.35% w/w, does not necessarily mean that the crystallisation form of azithromycin is different from the crystallisation form of azithromycin in the form of a monohydrate. We have found that the X-ray powder diffraction pattern of azithromycin according to the present invention is corresponding to the X-ray powder diffraction pattern which is disclosed for azithromycin in the form of a monohydrate as disclosed in EP 941 999, Figure 2, and EP 984 020, Figure 2; and is substantially

different from the X-ray powder diffraction pattern of azithromycin in the form of a dihydrate as disclosed in EP 941 999, Figure 1, and in EP 984 020, Figure 4.

Azithromycin according to the present invention is substantially crystalline and maintains its X-ray powder diffraction pattern, i.e. it maintains its crystalline structure, within at least 2  
5 weeks, e.g. up to 6 weeks and more, such as 2 to 6 weeks, under normal, e.g. normal air, humidity conditions, e.g. even at elevated temperatures.

Azithromycin according to the present invention may be further defined by its low content of azithromycin degradation products. E.g. we have found that in a sample of azithromycin  
10 according to the present invention practically no azithromycin degradation occurs, when setting out said sample to normal, e.g. normal air, humidity conditions, such as 70% to 80%, e.g. 75% humidity, within 2 to 6 weeks, e.g. within 6 weeks, and even longer, e.g. at elevated temperatures, such as temperatures above room temperatures, e.g. 35°C to 45°C, such as 40°C; e.g. we have found that the degradation of azithromycin according to the  
15 present invention under a temperature of 40°C in an environment of 75% humidity within 6 weeks is less than 2.0%, even less than 1.0% and even less than 0.5%, namely (around) 0.1%, whereas azithromycin in the form of a monohydrate having a water content of 2.8% to 3.6% shows a degradation of 2.5% already within 2 weeks, which degradation is increasing within 4 weeks, and is of almost 7% within 6 weeks under the same conditions.

20

In another aspect the present invention provides azithromycin in the form of a monohydrate, characterized in that in a sample thereof the degradation of azithromycin is less than 2%, even less than 1.5%, such as 0.05% to 1.0%, e.g. 0.05 to 0.5%, when setting out said  
25 sample to normal, e.g. normal air, humidity conditions, such as 75% environmental humidity, e.g. at elevated temperatures, such as of 40°C, within at least 2 weeks, e.g. within 2, e.g. 4, and e.g. even 6 weeks.

30

Azithromycin degradation which occurs under the above described conditions in a sample of azithromycin according to the present invention is within the percentage range of degradation products allowed by Pharmacopeias in commercial azithromycin forms.

Azithromycin according to the present invention may be further defined by its stable water content. E.g. we have found that in a sample of azithromycin according to the present invention the water content practically does not increase, e.g. the water content remains

essentially the same, when setting out said sample to normal, e.g. normal air, humidity conditions, such as 70% to 80%, e.g. 75% humidity, within 6 weeks, e.g. within 4 to 6 weeks, and even longer, e.g. at elevated temperatures, such as temperatures above room temperatures, e.g. 35°C to 45°C, such as 40°C; e.g. we have found that the water content  
5 of azithromycin according to the present invention at a temperature of 40°C, in an environment of 75% humidity remains substantially the same as in week 0 within 4 weeks and even 6 weeks.

In another aspect the present invention provides azithromycin in the form of a monohydrate,  
10 characterized in that in a sample thereof the water content remains substantially the same as in week 0, when setting out said sample to normal, e.g. normal air, humidity conditions, such as 75% environmental humidity, e.g. at elevated temperatures, such as temperatures above room temperatures, e.g. 35°C to 45°C, e.g. 40°C, for a period of 4 weeks, e.g. 4 to 6 weeks.

15

Azithromycin according to the present invention may be obtained e.g. as follows:

Azithromycin in any form, e.g. in free base form; and in the form of a salt, e.g. in the form of a hydrochloride, e.g. a dihydrochloride, acetate; and/or in the form of a solvate, e.g. in the form of a monohydrate, having a water content which is different from 4.0% to 6.5%, in  
20 anhydrous form, or in the form of a dihydrate, preferably in the form of a salt, may be e.g. used as a starting material. A solution of azithromycin in the form of a salt in a solvent may be produced, e.g. either by dissolving azithromycin in the form of a salt in a solvent; or by conversion of azithromycin in free form in a solvent into azithromycin in the form of a salt; e.g. by addition of an acid to azithromycin in solvent. A "solution" includes a suspension, in  
25 which at least a part of azithromycin (e.g. in the form of a salt) is dissolved. Appropriate acids include organic acids, for example formic acid or acetic acid, and inorganic acids, for example hydrochloric, hydrobromic, nitric or sulphuric acid, preferably hydrochloric acid or sulphuric acid. Solvent includes solvent which is appropriate to dissolve azithromycin in the form of a salt, e.g. including aqueous solvent. Aqueous solvent includes water or a mixture  
30 of water with organic solvent, e.g. one or more organic solvents, for example water miscible and water immiscible organic solvent, such as alcohols, e.g. methanol, ethanol, isopropanol; ketones such as acetone, methyl isobutyl ketone; alkyl carboxylic acid esters, e.g. (C<sub>1-4</sub>)alkyl carboxylic acid esters, of formic or acetic acid, e.g. methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate; aromatic hydrocarbons such as toluene, xylenes;

ethers, such as tetrahydrofuran, methyl t.butyl ether; chlorinated hydrocarbons such as methylene chloride; and amides such as monoalkyl and dialkyl amides, e.g. N-methyl formamide, N,N-dimethylacetamide, N,N-dimethylformamide; preferably water or a mixture of water with one or more alcohols, ketones, alkyl acetates; e.g. water, or aqueous solvent, such as water or water containing 0.5% to 20 % v/v; such as 1% to 15 % v/v of organic solvent. It is one advantage of the present invention that water in the absence of organic solvent may be used.

- Appropriate reaction conditions for the production of a solution of azithromycin in the form of a salt according to the process of the present invention include, e.g.
- 10 (i) A temperature at which azithromycin is not degraded, e.g. including a temperature range of -20°C to 90°C , such as 0°C to 70°C,
  - (ii) An appropriate pressure, e.g. atmospheric pressure, and a pressure which is above or below atmospheric pressure;
  - (iii) Appropriate dilution, e.g. a dilution range of 1 g to 500 g of azithromycin in the form  
15 used as a starting material, per litre of solvent.

A resulting solution of azithromycin in the form of a salt in a solvent may be optionally purified as appropriate, e.g. by filtration, charcoal treatment; in order to remove impurities. The pH of an, e.g. purified, solution of azithromycin in the form of a salt may be adjusted to an pH where azithromycin is present in free form, including e.g. a pH of, e.g. ca., 8.0 to  
20 13.0, such as 9.0 to 12.0, e.g. 10.0 to 11.0; e.g. by addition of a base to a solution of azithromycin in the form of a salt in a solvent. A "solution" of azithromycin in free form includes a suspension, in which at least a part of azithromycin is dissolved. Appropriate bases include bases which are suitable for pH adjustment, e.g. inorganic bases, such as ammonia or alkali-, e.g. sodium, potassium; earth alkali-, e.g. calcium-, magnesium-; and  
25 ammonium-  
-hydroxide, -carbonate, -hydrogencarbonate; and organic bases, such as amines, e.g. alkyl amines; and a mixture of individual bases, e.g. individual bases as described above. A base is preferably a hydroxide, e.g. sodium, or ammonia; preferably in aqueous solution.

Azithromycin in free form and in the form of a stable crystalline monohydrate may  
30 precipitate from the solution and may be isolated, e.g. analogously to a method as conventional, e.g. by centrifugation or filtration; and may be dried at appropriate temperatures, e.g. including a temperature range of 20°C to 80°C, e.g. under atmospheric pressure or under vacuum; until a water content of 4.0% to 6.5% is achieved. Crystalline



azithromycin in the form of a monohydrate may be obtained comprising from 4.0% to 6.5% of water.

In another aspect the present invention provides a process for the production of azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% of water, said  
5 process comprising the steps

- (i) adjusting the pH of a solution of azithromycin in the form of a salt wherein the solvent is selected from water or a mixture of water and organic solvent,
- (ii) isolating azithromycin of formula I in the form of a monohydrate, and
- (iii) drying to obtain azithromycin in the form of a monohydrate comprising from 4.0% to  
10 6.5% of water.

When solely water is used as a solvent azithromycin according to the present invention may be obtained, substantially free of organic solvent. Substantially free includes an analytically undetectable amount up to an analytically detectable amount of 0.5% w/w of organic  
15 solvent; which is an amount of organic solvents; which is within the range which European Pharmacopoeias define as appropriate for pharmaceutical ingredients, e.g for solvents with low toxic potential (Class 3 solvents).

In another aspect the present invention provides azithromycin in the form of a crystalline  
20 monohydrate, which is substantially free of organic solvent.

Azithromycin according to the present invention, is useful in the production of a pharmaceutical composition comprising azithromycin as an active ingredient.

25 In another aspect the present invention provides a pharmaceutical composition, comprising, e.g. essentially consisting of, azithromycin according to the present invention in association with at least one pharmaceutical carrier or diluent.

A pharmaceutical composition according to the present invention may contain the same  
30 concentrations of azithromycin and may be used for the same indications in the same dosage ranges as a known pharmaceutical composition comprising azithromycin in the form of a dihydrate, e.g. as is currently on the market.

### Examples

In the following examples all temperatures are in degree Centigrade and are uncorrected.

- 5 The X-ray powder diffraction pattern of azithromycin in the form of a monohydrate obtained according to the following example corresponds to that of azithromycin in the form of a monohydrate. Azithromycin in the form of a monohydrate obtained according to the following example maintains its crystallinity and its X-ray powder diffraction pattern and contains substantially no degradation products when kept for 6 weeks under normal air
- 10 humidity conditions at elevated temperatures.

Water content (% w/w) is determined by the K.Fischer

**Example**

To a suspension of 20 g of azithromycin in 83 ml of water, HCl is added until dissolution occurs. The solution obtained is filtrated, in order to remove undissolved particles, and the filtrate obtained is added dropwise to 103 ml of water whilst adjusting the pH to 10 to 11 by addition of 20% NaOH at a temperature of ca. 55°C. A solid precipitates, is filtrated off, washed and dried until a water content of 4.0 to 6.5% is achieved. 18.4 g of azithromycin in the form of a monohydrate in crystalline form are obtained. Water content: 6.0%  
Water content after 2 days at room temperature under normal air humidity conditions: 6.3%  
Water content after 13 days at room temperature under normal air humidity conditions: 6.3%

The X-ray diffraction powder pattern of azithromycin obtained corresponds to the X-ray diffraction powder pattern of azithromycin in the form of a monohydrate as disclosed in EP 941 999, Figure 2, and EP 984 020, Figure 2 on day 1, on day 2 and on day 13.

**15 Stability and comparison example**

Samples of azithromycin in the form of a monohydrate comprising

- 5.3% of water, and
- 2.8% of water

are set out for 6 weeks to an environment having a relative humidity of 75% at a temperature of 40°. Potency (content) of azithromycin, azithromycin degradation and water content in the samples are determined in week 0, week 2, week 4 and week 6. Potency and degradation are determined on azithromycin anhydrous basis by HPLC. The water content is determined by the Karl Fischer method.

Results are obtained

- 25
- for azithromycin comprising 5.3% of water as set out in TABLE 1 below,
  - for azithromycin comprising 2.8% of water as set out in TABLE 2 below:

**TABLE 1**

<b>WEEK</b>	<b>POTENCY (%)</b>	<b>Degradation (%)</b>	<b>WATER (%)</b>
0	99.8	-	5.3
2	98.9	0.1	5.3
4	99.5	0.1	5.3
6	99.5	0.1	5.3



TABLE 2

WEEK	POTENCY (%)	DEGRADATION (%)	WATER (%)
0	99.7	-	2.8
2	NO CONTROL	2.5	2.8
4	NO CONTROL	6.1	3.3
6	91.6	6.6	3.6

5 In TABLE 1 and TABLE 2

Crystalline azithromycin in both samples shows a X-ray powder diffraction pattern corresponding to that of azithromycin in the form of a monohydrate according to EP 941 999, Figure 2, and EP 984 020, Figure 2, in week 0 and in week 6.

The potency of azithromycin in % of each sample within the corresponding time period is

10 set out in TABLE 1 and TABLE 2 under "Potency (%)".

The degradation of azithromycin in % of each sample within the corresponding time period is set out in TABLE 1 and TABLE 2 under "Degradation (%)".

The water content in % of each sample within the corresponding time period is indicated in TABLE 1 and TABLE 2 under "Water (%)".

15

**Patent claims**

1. Azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% w/w of water.
- 5 2. Azithromycin in the form of a monohydrate, characterized in that in a sample thereof the degradation of azithromycin is less than 2% when setting out said sample to normal, humidity conditions at elevated temperatures, within at least 2 weeks.
- 10 3. Azithromycin in the form of a monohydrate, characterized in that in a sample thereof the water content remains substantially the same as in week 0, when setting out said sample to normal humidity conditions at elevated temperatures for a period of 4 weeks.
- 15 4. A pharmaceutical composition comprising azithromycin according to any one of claims 1 to 3 in association with at least one pharmaceutical carrier or diluent.
5. A process for the production of azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% of water, said process comprising the steps
  - (i) adjusting the pH of a solution of azithromycin in the form of a salt wherein the solvent is selected from water or a mixture of water and organic solvent,
  - 20 (ii) Isolating azithromycin in the form of a monohydrate, and
  - (iii) drying to obtain azithromycin in the form of a monohydrate comprising from 4.0% to 6.5% of water.